Diamyd Medical has received USD 13.9 million in connection with its divestment in Companion Medical
Diamyd Medical announces today that in connection with the previously announced acquisiton of Companion Medical, Inc by Medtronic plc., Diamyd Medical has now received approximately USD 13.9 million, corresponding to SEK 120 million. Depending on achievement of certain future milestones, some additional payments may be possible, and will then be communicated if they occur. About Diamyd MedicalDiamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant